32 results about "URINARY TRYPSIN INHIBITOR" patented technology

The invention relates to a urine protein enriching method. In the method, urine protein in urine is absorbed directly by an adsorbent in a urinal or a pee hopper, and the adsorbent for adsorbing the urine protein is conveyed to a working point for follow-up treatment; and based on the isoelectric point properties of specific urine protein, the urine protein such as urinary trypsin inhibitor, human urinary kininogenase, urokinase and the like is adsorbed directly and effectively by using the specific adsorbent such as ion exchange resin, and thus, the step of collecting the urine is avoided. The method does not influence sanitation of toilets obviously, reduces the cost of urine transportation substantially and solves a series of environmental problems.

The invention relates to a urinary protein enriching method which comprises the steps of directly adsorbing urinary proteins in urine in urinals or urinating buckets with filter cloth bags loaded with modified silica gel, and transporting the urinary protein adsorbed filter cloth bags to working points for subsequent treatment. According to the method, the isoelectric point property of specific urinary proteins is utilized, and urinary proteins such as urinary trypsin inhibitors, human urinary kininogenase, urokinase and the like are effectively absorbed directly by using the modified silica gel, macroporous resin, chitin, ionic resin and the like, so that a urine collecting step is avoided. The method is free of obvious influence on sanitary conditions of toilets, and the cost for urine transportation and a series of environmental problems resulting from urine transportation are greatly reduced.

The invention relates to an affinity medium for human urinary trypsin inhibitor, formed by connecting an affinity ligand for human urinary trypsin inhibitor with a chromatography medium. Preferably, the affinity ligand for human urinary trypsin inhibitor is an analogue of the site S1 of serine protease, the chromatography medium is Sepharose, chitosan, silica gel and ceramic particles, and the affinity ligand for human urinary trypsin inhibitor is connected with the chromatography medium by using cyanuric chloride as a spacer arm. A synthesis method for the affinity medium for human urinary trypsin inhibitor, and a method for purifying human urinary trypsin inhibitor in a large scale by using the affinity medium for human urinary trypsin inhibitor are further provided. Human urinary trypsin inhibitor can be rapidly separated and purified in a large scale by using the affinity medium for human urinary trypsin inhibitor, and human urinary trypsin inhibitor pure product can be obtained in case of only one-step affinity chromatography; and the human urinary trypsin inhibitor pure product is short in the consumed time of whole purification step, high in the recovery rates of protein and activity, and suitable for large-scale popularization and application.

The invention relates to a rescue medicament in the field of medical treatment, in particular to a rescue medicament, namely ulinastatin or a urinary trypsin inhibitor (UTI) for toxic shock caused by acute abdomen (particularly mesenteric angiemphraxis and the like). The medicament is a preferred medicament for the toxic shock. In the pharmacodynamic study of the ulinastatin for resisting shock, the ulinastatin also can improve the average arterial blood pressure and the average arterial blood flow of superior mesenteric artery occlusion shock of rats, and has an extremely better effect on shock rescue.

The invention discloses a method for separating urokinase from a human urinary trypsin inhibitor. The method comprises the following steps: regulating pH of a solution containing the urokinase and the human urinary trypsin inhibitor; slowly adding ammonium sulfate powder while stirring until the solution generates obvious protein precipitation; regulating the pH to 9.0 plus or minus 0.6; after standing, centrifuging or adding diatomite for filtering, collecting the precipitation rich in the urokinase, and obtaining the urokinase; continuing to adding ammonium sulfate into supernatant while stirring to dissolve the ammonium sulfate; and after standing, centrifuging or adding diatomite for filtering, collecting the precipitation 2 rich in the human urinary trypsin inhibitor, and obtaining the human urinary trypsin inhibitor. The method is simple, convenient and feasible and has a short period, the UK and UTI activity is effectively protected, the UK degradation is reduced, the UK quality is increased, special equipment is not needed, and the invested cost of the equipment is reduced.

The invention discloses a method for purifying a human urinary trypsin inhibitor (hUTI). The method comprises the following steps that: a, a solution containing the urinary trypsin inhibitor and cation exchange resin are contacted, so that the urinary trypsin inhibitor is adsorbed on the cation exchange resin; and b, a pH1-7 buffering liquid is used to elute the urinary trypsin inhibitor adsorbed on the cation exchange resin to obtain purified urinary trypsin inhibitor. The method is simple and high-efficient; and an obtained product has high purity.

The invention relates to a urine protein extraction method, in particular to a method for preparing a crude human urine kininogenase product.According to the method for preparing the crude human urine kininogenase product, anion exchange resin is adopted as an adsorbent to adsorb urine protein in urine, then the urine protein adsorbing resin is collected and eluted in a centralized mode, the eluant is used for adsorbing human urine kininogenase through cation exchange resin, and therefore human urine kininogenase and a human urine trypsin inhibitor are separated.Through the method for preparing the crude human urine kininogenase product, human urine kininogenase and the human urine trypsin inhibitor can be effectively separated, subsequent purification of human urine kininogenase and the human urine trypsin inhibitor is convenient, the purification rate is increased, co-production of two crude protein products is realized, and production cost can be greatly reduced.

The invention relates to a method for inactivating virus contained in a trypsin inhibitor extracted from human urine. The method comprises the following steps of dissolving a raw urinary trypsin inhibitor extracted from human urine in a buffer solution and heating at 60 DEG C; then eluting after being adsorbed on a DEAE (diethyl-aminoethanol) chromatographic column so as to obtain DEAE eluate; next sampling the DEAE eluate in ammonium sulfate solution and adsorbing on a hydrophobic chromatography column, then eluting with ammonium sulfate solution of 1M so as to obtain hydrophobic eluate; and after ultrafiltration of the hydrophobic eluate, incubating at low pH, and carrying out gel filtration chromatography to obtain the urinary trypsin inhibitor with virus inactivated. According to the method, a plurality of virus activation methods are utilized comprehensively, especially the two virus inactivation methods of thermally treating firstly and then incubating at low pH, and other separating medium are utilized for realizing inactivation of various virus, so that the inactivation effect of virus contained in the trypsin inhibitor extracted from human urine is further improved, and drug use safety is improved.

The invention belongs to the technical field of medicines, and particularly relates to a method for large-scale production of high-purity ulinastatin (namely human urinary trypsin inhibitor). The method comprises the following steps: mixing chitosan and alginate with urine after preliminary filtration so as to obtain a mixture, and then purifying the mixture in a manner combining ultrafiltration and ethanol fractional precipitation. The method provided by the invention is convenient to operate, high in controllability, simple in purification technology, and suitable for large-scale production; besides, the yield of the ulinastatin is as high as 72%, the molecular weight of protein obtained through purification is 66800D-67200D, and the activity of the ulinastatin for restraining trypsin is higher than 4780IU/mg protein.

The invention discloses novel application of a recombinant human urinary trypsin inhibitor. According to the experimental research on animals, the recombinant human urinary trypsin inhibitor has the effects of regulating expression of DC surface molecules CD80, CD86 and MHC-II, influencing T cell proliferation and differentiation, improving maturation state of DC through the expression of surface molecules CD80, CD86 and MHC-II, and further influencing T cell proliferation and differentiation and relieving and regulating negative immunoregulation of T lymphocytes. The recombinant human urinary trypsin inhibitor can achieve the effects of relieving an immunosuppressive state caused by sepsis, particularly cellular immunosuppression, and improving the survival rate of mice suffering from sepsis and the symptoms of sepsis, and can be used for treating sepsis.